Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Study protocol

The use of erlotinib in daily practice: a study on adherence and patients' experiences

Authors: Lonneke Timmers, Christel CLM Boons, Dirk Mangnus, Josee E Moes, Eleonora L Swart, Epie Boven, Egbert F Smit, Jacqueline G Hugtenburg

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Adherence to pharmacological therapy is a complex and multi-factorial issue that can substantially alter the outcome of treatment. It has been shown that cancer patients, especially when using long-term medication, have similar adherence rates to those of patients with other diseases. The consequences of poor adherence are poor health outcomes and increased health care costs. Only few studies have focused on the use of oral anticancer agents in daily practice. Information about the reasons for non-adherence is essential for the development of interventions that may increase adherence. This paper presents the CAPER-erlotinib protocol, which is designed to study the relationship between adherence to erlotinib and both the plasma concentration and side-effects in patients with NSCLC. Further, the relationships between patient characteristics, disease characteristics, side-effects, quality of life, patient beliefs and attitude towards disease and medication, dose adjustments, reasons for discontinuation and plasma concentration of erlotinib will be explored.

Methods/Design

In this prospective observational cohort study 65 NSCLC patients of 18 years or older starting treatment with erlotinib will be followed for a period up to 16 weeks. The main study parameters are adherence, the plasma concentration of erlotinib and the number and grade of side-effects. At baseline and on erlotinib treatment in weeks 3-4, 8-9, 12 and 15-16, patients will be asked to fill out a questionnaire. In weeks 3-4, 8-9 and 15-16 blood samples are collected, which will be analysed for plasma concentration of erlotinib. Adherence will be measured using a medication event monitoring system.

Discussion

The present study aims to get more insight into patients' experiences with the use of erlotinib in daily practice and the various aspects that govern adherence. We hypothesize that side-effects play an important role in the way patients use erlotinib. We expect that the present study will provide valuable knowledge which will be useful for health care professionals to develop interventions to support patients. This approach will improve the adherence and persistence with the use of erlotinib in order to derive optimal benefit from the medication.

Trial Registration

NTR1830
Literature
1.
Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, Morris R, Price M: Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006, 17 (2): 205-210.CrossRefPubMed
2.
Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997, 15 (1): 110-115.PubMed
3.
Kruse GB, Amonkar MM, Smith G, Skonieczny DC, Stavrakas S: Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008, 14 (9): 844-857.PubMed
4.
Twelves CJ: Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer. 2006, 6 (4): 278-287. 10.3816/CCC.2006.n.046.CrossRefPubMed
5.
Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT: The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer. 2006, 10/28 (14): 2381-8. 95(1):27-34
6.
Sabaté E: Adherence to long-term therapies Evidence for action. 2003, Geneva: World Health Organization
7.
Tebbi CK: Treatment compliance in childhood and adolescence. Cancer. 1993, 71 (10 Suppl): 3441-3449.CrossRefPubMed
8.
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK: Medication compliance and persistence: terminology and definitions. Value Health. 2008, 11 (1): 44-47. 10.1111/j.1524-4733.2007.00213.x.CrossRefPubMed
9.
Ruddy K, Mayer E, Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009, 59 (1): 56-66. 10.3322/caac.20004.CrossRefPubMed
10.
Partridge AH, Avorn J, Wang PS, Winer EP: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002, 94 (9): 652-661.CrossRefPubMed
11.
Yeaw J, Benner JS, Walt JG, Sian S, Smith DB: Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009, 15 (9): 728-740.PubMed
12.
Klein CE, Kastrissios H, Miller AA, Hollis D, Yu D, Rosner GL, Grinblatt DL, Larson RA, Ratain MJ: Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006, 57 (2): 199-206. 10.1007/s00280-005-0023-6.CrossRefPubMed
13.
Waterhouse DM, Calzone KA, Mele C, Brenner DE: Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993, 11 (6): 1189-1197.PubMed
14.
Nilsson JLG, Andersson K, Bergkvist A, Bjorkman I, Brismar A, Moen J: Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care (Engl). 2006, 15 (3): 235-237. 10.1111/j.1365-2354.2006.00645.x.CrossRef
15.
Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, Martiat P, Mineur P, van Eygen K, MacDonald K, De Geest S, Altrecht T, Abraham I: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009, 113 (22): 5401-5411. 10.1182/blood-2008-12-196543.CrossRefPubMed
16.
Partridge AH, Wang PS, Winer EP, Avorn J: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003, 21 (4): 602-606. 10.1200/JCO.2003.07.071.CrossRefPubMed
17.
Ruddy KJ, Partridge AH: Adherence with adjuvant hormonal therapy for breast cancer. Ann Oncol. 2009, 20 (3): 401-402.CrossRefPubMed
18.
Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kazlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010, 28 (14): 2381-2388. 10.1200/JCO.2009.26.3087.CrossRefPubMed
19.
Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD: Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010, 26 (12): 2861-2869. 10.1185/03007995.2010.533648.CrossRefPubMed
20.
McAndrew LM, Musumeci-Szabo TJ, Mora PA, Vileikyte L, Burns E, Halm EA, Leventhal EA, Leventhal H: Using the common sense model to design interventions for the prevention and management of chronic illness threats: from description to process. Br J Health Psychol. 2008, 13: 195-204. 10.1348/135910708X295604.CrossRefPubMed
21.
Broadbent E, Petrie KJ, Main J, Weinman J: The brief illness perception questionnaire. J Psychosom Res. 2006, 60: 631-637. 10.1016/j.jpsychores.2005.10.020.CrossRefPubMed
22.
Horne R, Weinman J, Hankins M: The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychology and Health. 1999, 14: 1-24. 10.1080/08870449908407311.CrossRef
23.
Horne R, Cooper V, Gellaitry G, Date HL, Fisher M: Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007, 1/45 (3): 334-341.PubMed
24.
Jonsdottir H, Friis S, Horne R, Pettersen KI, Reikvam A, Andreassen OA: Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand. 2009, 119 (1): 78-84. 10.1111/j.1600-0447.2008.01279.x.CrossRefPubMed
25.
Mardby AC, Akerlind I, Jorgensen T: Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns. 2007, 69 (1-3): 158-164.CrossRefPubMed
26.
Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, Raaijmakers JAM, et al: Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res. 2008, 64 (1): 47-54. 10.1016/j.jpsychores.2007.07.016.CrossRefPubMed
27.
Schuz B, Marx C, Wurm S, Warner LM, Ziegelmann JP, Schwarzer R, et al: Medication beliefs predict medication adherence in older adults with multiple illnesses. J Psychosom Res. 2011, 70 (2): 179-187. 10.1016/j.jpsychores.2010.07.014.CrossRefPubMed
28.
Eliasson L, Clifford S, Barber N, Marin D: Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011, 35 (5): 626-630. 10.1016/j.leukres.2010.10.017.CrossRefPubMed
29.
Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al: Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009, 101 (23): 1624-1632. 10.1093/jnci/djp386.CrossRefPubMedPubMedCentral
30.
31.
Roche Registration Ltd: Tarceva: European Public Assessment Report Product Information. Annex I: Summary of product characteristics. 2010, European Medicines Agency
32.
Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001, 19 (13): 3267-3279.PubMed
33.
Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, et al: Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008, 26 (7): 1119-1127. 10.1200/JCO.2007.13.1128.CrossRefPubMed
34.
Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al: Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004, 22 (16): 3238-3247. 10.1200/JCO.2004.11.057.CrossRefPubMed
35.
Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007, 13 (13): 3913-3921. 10.1158/1078-0432.CCR-06-2610.CrossRefPubMed
36.
Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, et al: Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006, 80 (2): 136-145. 10.1016/j.clpt.2006.04.007.CrossRefPubMed
37.
Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, et al: Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther. 2007, 6 (3): 432-438. 10.4161/cbt.6.3.3763.CrossRefPubMed
38.
Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, et al: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006, 12 (7 Pt 1): 2166-2171.CrossRefPubMed
39.
Ling J, Fettner S, Lum BL, Riek M, Rakhit A: Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs. 2008, 19 (2): 209-216. 10.1097/CAD.0b013e3282f2d8e4.CrossRefPubMed
40.
Butler JA, Peveler RC, Roderick P, Horne R, Mason JC: Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation. 2004, 77 (5): 786-789. 10.1097/01.TP.0000110412.20050.36.CrossRefPubMed
41.
Horne R, Hankins M, Jenkins R: The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001, 10 (3): 135-140. 10.1136/qhc.0100135.CrossRefPubMedPubMedCentral
42.
Aaronson NK, Muller M, Essink-Bot ML, Fekkes M, Sanderman R, te Velde A, Verrips E: Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations. J Clin Epidemiol. 1998, 51 (11): 1055-1068. 10.1016/S0895-4356(98)00097-3.CrossRefPubMed
43.
Hurst NP, Ruta DA, Kind P: Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Br J Rheumatol. 1998, 37 (8): 862-869. 10.1093/rheumatology/37.8.862.CrossRefPubMed
44.
Olivieri NF, Matsui D, Hermann C, Koren G: Compliance assessed by the Medication Event Monitoring System. Arch Dis Child. 1991, 66: 1399-1402. 10.1136/adc.66.12.1399.CrossRefPubMedPubMedCentral
45.
Denhaerynck K, Schäfer-Keller P, Young J, Steiger J, Bock A, De Geest S: Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients. BMC Medical Research Methodology. 2008, 8: 5-10.1186/1471-2288-8-5.CrossRefPubMedPubMedCentral
Metadata
Title
The use of erlotinib in daily practice: a study on adherence and patients' experiences
Authors
Lonneke Timmers
Christel CLM Boons
Dirk Mangnus
Josee E Moes
Eleonora L Swart
Epie Boven
Egbert F Smit
Jacqueline G Hugtenburg
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-284

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Fish consumption and the risk of gastric cancer: systematic review and meta-analysis

Research article

Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer

Research article

Oxidative stress and antioxidant status in primary bone and soft tissue sarcoma

Research article

Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines

Research article

Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer

Research article

Identification and Regulation of c-Myb Target Genes in MCF-7 Cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits